当前位置:首页 - 行情中心 - 百诚医药(301096) - 财务分析 - 现金流量表

百诚医药

(301096)

  

流通市值:51.72亿  总市值:67.98亿
流通股本:8309.00万   总股本:1.09亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金99,846,567.09404,491,154.76237,057,558.97197,166,542.1
  收到的税费返还-34,063.64--
  收到其他与经营活动有关的现金18,568,665.5130,031,195.6216,775,420.5214,363,165.11
  经营活动现金流入小计118,415,232.6434,556,414.02253,832,979.49211,529,707.21
  购买商品、接受劳务支付的现金32,496,586.33210,575,468.36173,731,984.45107,851,623.47
  支付给职工以及为职工支付的现金61,550,794.66269,492,748.92210,960,922.9150,080,765.71
  支付的各项税费6,583,819.4211,740,535.2410,504,504.019,644,269.85
  支付其他与经营活动有关的现金24,635,112.2597,392,351.3938,421,185.3558,372,287.23
  经营活动现金流出小计125,266,312.66589,201,103.91433,618,596.71325,948,946.26
  经营活动产生的现金流量净额-6,851,080.06-154,644,689.89-179,785,617.22-114,419,239.05
二、投资活动产生的现金流量:
  收回投资收到的现金2,150,0004,335,622.58--
  处置固定资产、无形资产和其他长期资产收回的现金净额-423,095.56289,098.8616,287.15
  收到的其他与投资活动有关的现金29,556,160.43413,746,697.38308,244,674.62238,624,269.71
  投资活动现金流入小计31,706,160.43418,505,415.52308,533,773.48238,640,556.86
  购建固定资产、无形资产和其他长期资产支付的现金41,090,198.5397,917,790.1184,160,403.3858,497,334.09
  投资支付的现金-34,870,00016,634,377.426,650,000
  支付其他与投资活动有关的现金9,483,548.32406,522,985.01396,221,684309,666,134.38
  投资活动现金流出小计50,573,746.85539,310,775.12497,016,464.8374,813,468.47
  投资活动产生的现金流量净额-18,867,586.42-120,805,359.6-188,482,691.32-136,172,911.61
三、筹资活动产生的现金流量:
  取得借款收到的现金290,000,0001,061,282,342.62816,782,342.6510,000,000
  收到其他与筹资活动有关的现金411,113.1---
  筹资活动现金流入小计290,411,113.11,061,282,342.62816,782,342.6510,000,000
  偿还债务支付的现金152,961,527.78899,878,047.62491,582,342.6266,400,000
  分配股利、利润或偿付利息支付的现金4,975,481.0820,521,855.4715,768,956.19,462,858.54
  支付其他与筹资活动有关的现金258,029.621,039,056.57524,223.68231,335.24
  筹资活动现金流出小计158,195,038.48921,438,959.66507,875,522.38276,094,193.78
  筹资活动产生的现金流量净额132,216,074.62139,843,382.96308,906,820.22233,905,806.22
四、汇率变动对现金及现金等价物的影响-2,550.9-78,180.21312,756.01326,514.9
五、现金及现金等价物净增加额106,494,857.24-135,684,846.74-59,048,732.31-16,359,829.54
  加:期初现金及现金等价物余额280,476,499.32416,161,346.06416,161,346.06416,161,346.06
  期末现金及现金等价物余额386,971,356.56280,476,499.32357,112,613.75399,801,516.52
补充资料:
  净利润--90,395,530.08-3,098,160.54
  资产减值准备-33,684,968.18-6,728,581.21
  固定资产和投资性房地产折旧-153,346,776.61-77,147,845.07
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-153,346,776.61-77,147,845.07
  无形资产摊销-3,615,183.44-1,833,568.4
  长期待摊费用摊销-582,129.27-294,791.88
  处置固定资产、无形资产和其他长期资产的损失--218,302.93--
  固定资产报废损失-1,088.29--
  财务费用-21,176,464.26-9,673,278.07
  投资损失-11,796,809.44--1,688,430.57
  递延所得税--1,317,235.31-802,123.12
  其中:递延所得税资产减少--1,317,235.31-802,123.12
  存货的减少--5,644,593.86--28,470,143.12
  经营性应收项目的减少--211,649,108.73--161,045,313.25
  经营性应付项目的增加--71,930,986.37--23,135,554.11
  其他-1,625,076.39--
  现金的期末余额-280,476,499.32-399,801,516.52
  减:现金的期初余额-416,161,346.06-416,161,346.06
  现金及现金等价物的净增加额--135,684,846.74--16,359,829.54
公告日期2026-04-242026-04-242025-10-252025-08-27
审计意见(境内)标准无保留意见
TOP↑